Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,941 |
Ending reported balance
After 2026-05-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 97,143 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Row 2 · 2026-05-01 · Sale · Disposed 16,145 · Balance 80,998 F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 3 · 2026-05-01 · Sale · Disposed 1,057 · Balance 79,941 F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F4: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F5: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F6: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
F3: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F6: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,057 | $8.97 | $9,481.29 |
DisclosureSEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 3 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,941 F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F4 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 16,145 | $8.36 | $134,972.20 |
DisclosureSEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,998 F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · derivative · entry 4 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F6 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,143 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 20:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,086 | $8.87 | $62,852.82 |
DisclosureSEC source: 0001628280-25-040670 · wk-form4_1755549206.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,799 F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025 and May 25, 2025, respectively. F2 · price: All shares sold at an exact price of $8.87. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000108 · wk-form4_1746232265.xml · derivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000108 · wk-form4_1746232265.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,885 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| March 12, 2025 Filed Mar 12, 2025 22:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,000 | $5.73 | $57,300.00 |
DisclosureSEC source: 0001367644-25-000059 · wk-form4_1741817583.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,482 Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,000 | $6.11 | $61,100.00 |
DisclosureSEC source: 0001367644-24-000098 · wk-form4_1717704966.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,482 Read SEC document |
| May 29, 2024 Filed May 31, 2024 19:02 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,830 | $4.61 | $8,436.30 |
DisclosureSEC source: 0001367644-24-000095 · wk-form4_1717182155.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,482 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a grandfathered trading plan adopted by Ms. Zoon on June 15, 2022. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000077 · wk-form4_1716945262.xml · derivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000077 · wk-form4_1716945262.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,312 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,089 | $5.78 | $6,294.42 |
DisclosureSEC source: 0001367644-24-000065 · wk-form4_1716498920.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,882 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a grandfathered trading plan adopted by Ms. Zoon on June 15, 2022. Read SEC document |
| June 02, 2023 Filed Jul 24, 2023 12:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,830 | $8.35 | $15,280.50 |
DisclosureSEC source: 0001367644-23-000137 · wk-form4_1690201708.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,971 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ms. Zoon. Read SEC document |
| May 25, 2023 Filed May 30, 2023 23:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000110 · wk-form4_1685488183.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,501 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 25, 2023 Filed Jul 24, 2023 12:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,700 | $8.38 | $14,246.00 |
DisclosureSEC source: 0001367644-23-000137 · wk-form4_1690201708.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,801 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ms. Zoon. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,173 | $31.52 | $36,972.96 |
DisclosureSEC source: 0001367644-22-000101 · wf-form4_165515135039033.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,654 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000088 · wf-form4_165402799025784.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,827 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,996 | $35.53 | $70,917.88 |
DisclosureSEC source: 0001367644-22-000077 · wf-form4_165350953758392.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,381 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,139 | $56.48 | $177,290.72 |
DisclosureSEC source: 0001367644-21-000101 · wf-form4_162214773924582.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,377 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2021, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.11 to $56.86. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:11 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000095 · wf-form4_162189066691622.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,516 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 20:43 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,000 | $130.27 | $130,270.00 |
DisclosureSEC source: 0001367644-20-000128 · wf-form4_159717860987210.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| May 26, 2020 Filed May 27, 2020 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,093 | $85.10 | $348,322.08 |
DisclosureSEC source: 0001367644-20-000084 · wf-form4_159061362728074.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,489 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.14 to $86.28. Read SEC document |
| May 21, 2020 Filed May 26, 2020 13:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000080 · wf-form4_159049896921710.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,582 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,660 | $85.21 | $141,454.24 |
DisclosureSEC source: 0001367644-20-000065 · wf-form4_158948818627729.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,761 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:39 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 991 | $60.65 | $60,103.46 |
DisclosureSEC source: 0001367644-20-000027 · wf-form4_158353074503870.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,421 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions ranging from $60.6301 to $60.6850. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:11 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,000 | $54.31 | $54,314.00 |
DisclosureSEC source: 0001367644-19-000063 · wf-form4_157419786844482.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,412 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions ranging from $54.24 to $54.34. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 14:52 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,082 | $54.15 | $166,884.44 |
DisclosureSEC source: 0001367644-19-000061 · wf-form4_157357032406627.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,412 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F3 · price: The price reported is the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.69 to $54.72. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:44 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,509 | $56.12 | $84,692.02 |
DisclosureSEC source: 0001367644-19-000046 · wf-form4_156815185293314.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,494 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| May 28, 2019 Filed May 29, 2019 00:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,376 | $43.39 | $59,702.44 |
DisclosureSEC source: 0001567619-19-012278 · doc1.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,003 F3 · shares: The sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.58, inclusive. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012278 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,379 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 23:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,871 | $70.08 | $131,117.62 |
DisclosureSEC source: 0001567619-18-005458 · doc1.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,643 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.18, inclusive. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 23:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,371 | $69.48 | $164,738.03 |
DisclosureSEC source: 0001567619-18-005458 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,514 F1 · shares: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.90 to $70.14, inclusive. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 376 | $52.81 | $19,856.56 |
DisclosureSEC source: 0001140361-18-027683 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,885 Read SEC document |
| May 24, 2018 Filed May 24, 2018 20:34 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025519 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,638 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,377 | $51.15 | $70,433.55 |
DisclosureSEC source: 0001140361-18-025992 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,261 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 371 | $40.84 | $15,153.35 |
DisclosureSEC source: 0001140361-17-042137 · doc1.xml · nonDerivative · entry 2 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,743 F1 · security: Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.84 to $40.85, inclusive. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,371 | $38.94 | $92,336.94 |
DisclosureSEC source: 0001140361-17-042137 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,114 F1 · security: Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017. F3 · shares: The transactions reported in this row were effected pursuant to a Rule 10b5-1 plan adopted by Dr. Zoon. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.25, inclusive. Read SEC document |
| May 25, 2017 Filed May 26, 2017 18:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022484 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,485 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 14,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-085896 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,226 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.